Journal Mobile Options
Table of Contents
Vol. 24, No. 1, 2007
Issue release date: June 2007
Section title: Review Article
Dement Geriatr Cogn Disord 2007;24:1–19
(DOI:10.1159/000102567)

Is Antioxidant Therapy a Viable Alternative for Mild Cognitive Impairment? Examination of the Evidence

Ancelin M.-L.a · Christen Y.b · Ritchie K.a
aInserm, U888, University of Montpellier-1, Montpellier, and bIpsen, Paris, France
email Corresponding Author

Abstract

Therapeutic interventions for the prodromal stages of dementia are currently being sought with a view to delaying if not preventing disease onset. Uncertainty as to whether cognitive disorder in a given individual will progress towards dementia and adverse drug side effects has led to hesitancy on the part of drug regulators to instigate preventive pharmacotherapies. In this context, antioxidant therapies may provide a low-risk alternative, targeting very early biological changes. While a growing body of knowledge demonstrates both the importance of oxidative stress in the aetiology of dementia and the efficacy of antioxidant treatment in animal and cellular models, studies in humans are presently inconclusive. While some antioxidants, notably flavonoid- or vitamin-rich diets, appear to lower the relative risk for Alzheimer’s disease in humans in observational studies, these results must be interpreted in the light of the biological complexity of the relationship between oxidative stress and neurodegeneration, and the methodological and theoretical shortcomings of studies conducted to date. A clearer understanding of these factors will assist in the interpretation of the results of the intervention studies which are now being undertaken; these studies being the only current means of establishing efficacy for preventive drug treatment of Alzheimer’s disease.

© 2007 S. Karger AG, Basel


  

Key Words

  • Oxidative stress
  • Antioxidants
  • Vitamins
  • Ginkgo biloba
  • Mild cognitive impairment
  • Alzheimer’s disease

References

  1. Katzman R, Fox PJ: The world-wide impact of dementia: projections of prevalence and costs; in Mayeux R, Christen Y (eds): Epidemiology of Alzheimer’s Disease. From Gene to Prevention. Berlin, Springer, 1999, pp 1–17.
  2. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.
  3. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37–46.
  4. Finkel T, Holbrook NJ: Oxidants, oxidative stress and the biology of ageing. Nature 2000;408:239–247.
  5. Christen Y: Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71:621S–629S.
  6. Arlt S, Beisiegel U, Kontush A: Lipid peroxidation in neurodegeneration: new insights into Alzheimer’s disease. Curr Opin Lipidol 2002;13:289–294.
  7. Butterfield DA, Castegna A, Lauderback CM, Drake J: Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death. Neurobiol Aging 2002;23:655–664.
  8. Abramov AY, Canevari L, Duchen MR: Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 2004;24:565–575.
  9. Berlin D, Chong G, Chertkow H, Bergman H, Phillips NA, Schipper HM: Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI. Neurobiol Aging 2004;25:465–474.
  10. Robson KJ, Lehmann DJ, Wimhurst VL, Livesey KJ, Combrinck M, Merryweather-Clarke AT, et al: Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer’s disease. J Med Genet 2004;41:261–265.
  11. Behl C, Moosmann B: Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic approach. Free Radic Biol Med 2002;33:182–191.
  12. Luchsinger JA, Tang MX, Shea S, Mayeux R: Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60:203–208.
  13. Floyd RA, Hensley K: Oxidative stress in brain aging: implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 2002;23:795–807.
  14. Engelhart MJ, Ruitenberg A, Meijer J, Kiliaan A, van Swieten JC, Hofman A, et al: Plasma levels of antioxidants are not associated with Alzheimer’s disease or cognitive decline. Dement Geriatr Cogn Disord 2005;19:134–139.
  15. Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, Lussier-Cacan S, et al: Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer’s disease is related to the apolipoprotein E genotype. Free Radic Biol Med 1999;27:544–553.
  16. Tamaoka A, Miyatake F, Matsuno S, Ishii K, Nagase S, Sahara N, et al: Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer’s disease. Neurology 2000;54:2319–2321.
  17. Delibas N, Ozcankaya R, Altuntas I: Clinical importance of erythrocyte malondialdehyde levels as a marker for cognitive deterioration in patients with dementia of Alzheimer type: a repeated study in 5-year interval. Clin Biochem 2002;35:137–141.
  18. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ: Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 2002;59:972–976.
  19. De Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al: Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006;27:394–401.
  20. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, et al: Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer’s disease. Neurobiol Aging 2003;24:915–919.
  21. Berr C, Richard MJ, Roussel AM, Bonithon-Kopp C: Systemic oxidative stress and cognitive performance in the population-based EVA study. Etude du Vieillissement Arteriel. Free Radic Biol Med 1998;24:1202–1208.
  22. Berr C, Balansard B, Arnaud J, Roussel AM, Alperovitch A: Cognitive decline is associated with systemic oxidative stress: the EVA study. Etude du Vieillissement Arteriel. J Am Geriatr Soc 2000;48:1285–1291.
  23. Berr C, Richard MJ, Gourlet V, Garrel C, Favier A: Enzymatic antioxidant balance and cognitive decline in aging – the EVA study. Eur J Epidemiol 2004;19:133–138.
  24. Polidori MC, Mattioli P, Aldred S, Cecchetti R, Stahl W, Griffiths H, et al: Plasma antioxidant status, immunoglobulin G oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord 2004;18:265–270.
  25. Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, et al: Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer’s disease. Ann Neurol 2002;52:175–179.
  26. Beckman KB, Ames BN: The free radical theory of aging matures. Physiol Rev 1998;78:547–581.
  27. Christen Y: Proteins and mutations: a new vision (molecular) of neurodegenerative diseases. J Soc Biol 2002;196:85–94.
  28. Yao Y, Zhukareva V, Sung S, Clark CM, Rokach J, Lee VM, et al: Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology 2003;61:475–478.
  29. Behl C, Davis J, Cole GM, Schubert D: Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun 1992;186:944–950.
  30. Harkany T, Hortobagyi T, Sasvari M, Konya C, Penke B, Luiten PG, et al: Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:963–1008.
  31. Christen Y, Droy-Lefaix M-T, Pasquier C, Packer L: Effects of Ginkgo biloba extract (EGb 761) on Alzheimer’s disease; in Poli G, Cadenas E, Packer L (eds): Free Radicals in Brain Pathophysiology. New York, Dekker, 2000, pp 411–423.
  32. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R: The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 2000;12:1882–1890.
  33. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, et al: Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 2002;99:12197–1202.
  34. Colciaghi F, Borroni B, Zimmermann M, Bellone C, Longhi A, Padovani A, et al: Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis 2004;16:454–460.
  35. Stackman RW, Eckenstein F, Frei B, Kulhanek D, Nowlin J, Quinn JF: Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer’s disease by chronic Ginkgo biloba treatment. Exp Neurol 2003;184:510–520.
  36. Joseph JA, Denisova NA, Arendash G, Gordon M, Diamond D, Shukitt-Hale B, et al: Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr Neurosci 2003;6:153–162.
  37. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, et al: Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001;22:993–1005.
  38. Joseph JA, Shukitt-Hale B, Denisova NA, Prior RL, Cao G, Martin A, et al: Long-term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits. J Neurosci 1998;18:8047–8055.
  39. Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G, Calabrese V: Nutritional approaches to combat oxidative stress in Alzheimer’s disease. J Nutr Biochem 2002;13:444.
  40. Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DL, Reiter RJ, et al: Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997;17:1683–1690.
  41. Xiao XQ, Zhang HY, Tang XC: Huperzine A attenuates amyloid beta-peptide fragment 25–35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res 2002;67:30–36.
  42. Medina S, Martinez M, Hernanz A: Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1–42. Free Radic Res 2002;36:1179–1184.
  43. Bruce AJ, Malfroy B, Baudry M: beta-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. Proc Natl Acad Sci USA 1996;93:2312–2316.
  44. Suuronen T, Kolehmainen P, Salminen A: Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. Biochem Pharmacol 2000;59:1589–1595.
  45. Hayako H, Hirai K, Kato K: Idebenone attenuates amyloid β-peptide-induced cell death rate hippocampal neuronal cell cultures (abstract). Jpn J Pharmacol 1997;73:245P.
  46. Galli RL, Shukitt-Hale B, Youdim KA, Joseph JA: Fruit polyphenolics and brain aging: nutritional interventions targeting age-related neuronal and behavioral deficits. Ann NY Acad Sci 2002;959:128–132.
  47. Fukui K, Omoi NO, Hayasaka T, Shinnkai T, Suzuki S, Abe K, et al: Cognitive impairment of rats caused by oxidative stress and aging, and its prevention by vitamin E. Ann NY Acad Sci 2002;959:275–284.
  48. Yamazaki N, Kiyota Y, Take Y, Miyamoto M, Nagawa Y, Nagaoka A: Effects of idebenone on memory impairment induced in ischemic and embolization models of cerebrovascular disturbance in rats. Arch Gerontol Geriatr 1989;8:213–224.
  49. Liu R, Liu IY, Bi X, Thompson RF, Doctrow SR, Malfroy B, et al: Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. Proc Natl Acad Sci USA 2003;100:8526–8531.
  50. Cohen-Salmon C, Venault P, Martin B, Raffalli-Sebille MJ, Barkats M, Clostre F, et al: Effects of Ginkgo biloba extract (EGb 761) on learning and possible actions on aging. J Physiol Paris 1997;91:291–300.
  51. Rogers EJ, Milhalik S, Orthiz D, Shea TB: Apple juice prevents oxidative stress and impaired cognitive performance caused by genetic and dietary deficiencies in mice. J Nutr Health Aging 2004;8:92–97.
  52. Milgram NW, Zicker SC, Head E, Muggenburg BA, Murphey H, Ikeda-Douglas CJ, et al: Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Neurobiol Aging 2002;23:737–745.
  53. Mattson MP, Duan W, Lee J, Guo Z: Suppression of brain aging and neurodegenerative disorders by dietary restriction and environmental enrichment: molecular mechanisms. Mech Ageing Dev 2001;122:757–778.
  54. Casadesus G, Shukitt-Hale B, Joseph JA: Qualitative versus quantitative caloric intake: are they equivalent paths to successful aging? Neurobiol Aging 2002;23:747–769.
  55. Grodstein F, Chen J, Willett WC: High-dose antioxidant supplements and cognitive function in community-dwelling elderly women. Am J Clin Nutr 2003;77:975–984.
  56. Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, et al: Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000;54:1265–1272.
  57. Maxwell CJ, Hicks MS, Hogan DB, Basran J, Ebly EM: Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. Dement Geriatr Cogn Disord 2005;20:45–51.
  58. Paleologos M, Cumming RG, Lazarus R: Cohort study of vitamin C intake and cognitive impairment. Am J Epidemiol 1998;148:45–50.
  59. Jama JW, Launer LJ, Witteman JC, den Breeijen JH, Breteler MM, Grobbee DE, et al: Dietary antioxidants and cognitive function in a population-based sample of older persons: the Rotterdam Study. Am J Epidemiol 1996;144:275–280.
  60. Gale CR, Martyn CN, Cooper C: Cognitive impairment and mortality in a cohort of elderly people. BMJ 1996;312:608–611.
  61. Ortega RM, Requejo AM, Andres P, Lopez-Sobaler AM, Quintas ME, Redondo MR, et al: Dietary intake and cognitive function in a group of elderly people. Am J Clin Nutr 1997;66:803–809.
  62. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS: Vitamin E and cognitive decline in older persons. Arch Neurol 2002;59:1125–1132.
  63. Ortega RM, Requejo AM, Lopez-Sobaler AM, Andres P, Navia B, Perea JM, et al: Cognitive function in elderly people is influenced by vitamin E status. J Nutr 2002;132:2065–2068.
  64. Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS, Aggarwal NT, et al: Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr 2005;81:508–514.
  65. La Rue A, Koehler KM, Wayne SJ, Chiulli SJ, Haaland KY, Garry PJ: Nutritional status and cognitive functioning in a normally aging sample: a 6-year assessment. Am J Clin Nutr 1997;65:20–29.
  66. Morris MC, Beckett LA, Scherr PA, Hebert LE, Bennett DA, Field TS, et al: Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:121–126.
  67. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, et al: Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004;61:82–88.
  68. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, et al: Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002;287:3223–3229.
  69. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, et al: Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002;287:3230–3237.
  70. Andrieu S, Gillette S, Amouyal K, Nourhashemi F, Reynish E, Ousset PJ, et al: Association of Alzheimer’s disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 2003;58:372–377.
  71. Dartigues JF, Carcaillon L, Helmer C, Lechevallier N, Lafuma A, Khoshnood B: Vasodilators and nootropics as predictors of dementia and mortality in the PAQUID cohort. J Am Geriatr Soc, in press.
  72. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, et al: Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 1997;153:185–192.
  73. Lemeshow S, Letenneur L, Dartigues JF, Lafont S, Orgogozo JM, Commenges D: Illustration of analysis taking into account complex survey considerations: the association between wine consumption and dementia in the PAQUID study – Personnes Ages Quid. Am J Epidemiol 1998;148:298–306.
  74. Commenges D, Scotet V, Renaud S, Jacqmin-Gadda H, Barberger-Gateau P, Dartigues JF: Intake of flavonoids and risk of dementia. Eur J Epidemiol 2000;16:357–363.
  75. Leibovici D, Ritchie K, Ledesert B, Touchon J: The effects of wine and tobacco consumption on cognitive performance in the elderly: a longitudinal study of relative risk. Int J Epidemiol 1999;28:77–81.
  76. Truelsen T, Thudium D, Gronbaek M: Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology 2002;59:1313–1319.
  77. Ruitenberg A, van Swieten JC, Witteman JC, Mehta KM, van Duijn CM, Hofman A, et al: Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 2002;359:281–286.
  78. Mukamal KJ, Kuller LH, Fitzpatrick AL, Longstreth WT Jr, Mittleman MA, Siscovick DS: Prospective study of alcohol consumption and risk of dementia in older adults. JAMA 2003;289:1405–1413.
  79. Luchsinger JA, Tang MX, Siddiqui M, Shea S, Mayeux R: Alcohol intake and risk of dementia. J Am Geriatr Soc 2004;52:540–546.
  80. Espeland MA, Coker LH, Wallace R, Rapp SR, Resnick SM, Limacher M, et al: Association between alcohol intake and domain-specific cognitive function in older women. Neuroepidemiology 2006;27:1–12.
  81. Youdim KA, Spencer JP, Schroeter H, Rice-Evans C: Dietary flavonoids as potential neuroprotectants. Biol Chem 2002;383:503–519.
  82. Dufouil C, Tzourio C, Brayne C, Berr C, Amouyel P, Alperovitch A: Influence of apolipoprotein E genotype on the risk of cognitive deterioration in moderate drinkers and smokers. Epidemiology 2000;11:280–284.
  83. Tanaka N, Asada T, Kinoshita T, Yamashita F, Uno M: Alcohol consumption and risk of dementia. Lancet 2002;360:491.
  84. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease: the Alzheimer’s Disease Cooperative Study. N Engl J Med 1997;336:1216–1222.
  85. Kilander L, Ohrvall M: Alpha-tocopherol and Alzheimer’s disease. N Engl J Med 1997;337:572–573.
  86. Pincus MM: Alpha-tocopherol and Alzheimer’s disease. N Engl J Med 1997;337:572; author reply 573.
  87. Tabet N, Birks J, Grimley Evans J: Vitamin E for Alzheimer’s disease. Cochrane Database Syst Rev 2000;CD002854.
  88. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–2388.
  89. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF; North American EGb Study Group: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327–1332.
  90. Kanowski S, Hoerr R: Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 2003;36:297–303.
  91. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M: A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr Alzheimer Res 2005;2:541–551.
  92. Van Dongen MC, van Rossum E, Kessels AG, Sielhorst HJ, Knipschild PG: The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 2000;48:1183–1194.
  93. Van Dongen M, van Rossum E, Kessels A, Sielhorst H, Knipschild P: Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol 2003;56:367–376.
  94. Birks J, Grimley EV, Van Dongen M: Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002;CD003120.
  95. Adair JC, Knoefel JE, Morgan N: Controlled trial of N-acetylcysteine for patients with probable Alzheimer’s disease. Neurology 2001;57:1515–1517.
  96. Hager K, Marahrens A, Kenklies M, Riederer P, Munch G: Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. Arch Gerontol Geriatr 2001;32:275–282.
  97. Gutzmann H, Hadler D: Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre study. J Neural Transm Suppl 1998;54:301–310.
  98. Gutzmann H, Kuhl KP, Hadler D, Rapp MA: Safety and efficacy of idebenone versus tacrine in patients with Alzheimer’s disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry 2002;35:12–18.
  99. Weyer G, Erzigkeit H, Hadler D, Kubicki S: Efficacy and safety of idebenone versus tacrine in patients with Alzheimer’s disease: a double-blind, placebo controlled multicentre study. Hum Psychopharmacol 1996;11:53–65.
  100. Weyer G, Babej-Dolle RM, Hadler D, Hofmann S, Herrmann WM: A controlled study of 2 doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology 1997;36:73–82.
  101. Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, et al: Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease. Neurology 2003;61:1498–1502.
  102. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, et al: Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet 1991;337:1304–1308.
  103. Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, et al: Treatment of Alzheimer’s disease with clioquinol. Dement Geriatr Cogn Disord 2001;12:408–414.
  104. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, et al: Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60:1685–1691.
  105. Wolters M, Hickstein M, Flintermann A, Tewes U, Hahn A: Cognitive performance in relation to vitamin status in healthy elderly German women – the effect of 6-month multivitamin supplementation. Prev Med 2005;41:253–259.
  106. Mix JA, Crews WD Jr: A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol 2002;17:267–277.
  107. Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R: Ginkgo for memory enhancement: a randomized controlled trial. JAMA 2002;288:835–840.
  108. Martin A, Cherubini A, Andres-Lacueva C, Paniagua M, Joseph J: Effects of fruits and vegetables on levels of vitamins E and C in the brain and their association with cognitive performance. J Nutr Health Aging 2002;6:392–404.
  109. Dai Q, Borenstein AR, Wu Y, Jackson JC, Larson EB: Fruit and vegetable juices and Alzheimer’s disease: the Kame Project. Am J Med 2006;119:751–759.
  110. Yaffe K, Clemons TE, McBee WL, Lindblad AS: Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology 2004;63:1705–1707.
  111. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC: Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450–1456.
  112. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC: Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444–1449.
  113. Bowry VW, Ingold KU, Stocker R: Vitamin E in human low-density lipoprotein: when and how this antioxidant becomes a pro-oxidant. Biochem J 1992;288:341–344.
  114. Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P, Lunec J: Vitamin C exhibits pro-oxidant properties. Nature 1998;392:559.
  115. Halliwell B: The antioxidant paradox. Lancet 2000;355:1179–1180.
  116. Christen S, Woodall AA, Shigenaga MK, Southwell-Keely PT, Duncan MW, Ames BN: gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: physiological implications. Proc Natl Acad Sci USA 1997;94:3217–3222.
  117. Tangney CC, Bienias JL, Evans DA, Morris MC: Reasonable estimates of serum vitamin E, vitamin C, and beta-cryptoxanthin are obtained with a food frequency questionnaire in older black and white adults. J Nutr 2004;134:927–934.
  118. Riviere S, Lauque S, Vellas B: Health promotion programme: nutrition and Alzheimer’s disease. J Nutr Health Aging 1998;2:101–106.
  119. Meydani M: Antioxidants in the prevention of chronic diseases. Nutr Clin Care 2002;5:47–49.
  120. Shea TB, Rogers E, Ashline D, Ortiz D, Sheu MS: Apolipoprotein E deficiency promotes increased oxidative stress and compensatory increases in antioxidants in brain tissue. Free Radic Biol Med 2002;33:1115–1120.
  121. McCaddon A, Hudson P, Hill D, Barber J, Lloyd A, Davies G, et al: Alzheimer’s disease and total plasma aminothiols. Biol Psychiatry 2003;53:254–260.
  122. Miyata M, Smith JD: Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14:55–61.
  123. Willett WC, Stampfer MJ: Clinical practice: What vitamins should I be taking, doctor? N Engl J Med 2001;345:1819–1824.
  124. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, et al: Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005;293:1338–1347.
  125. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al: Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA 2005;294:56–65.
  126. Laurin D, Masaki KH, Foley DJ, White LR, Launer LJ: Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study. Am J Epidemiol 2004;159:959–967.
  127. Shukitt-Hale B, Smith DE, Meydani M, Joseph JA: The effects of dietary antioxidants on psychomotor performance in aged mice. Exp Gerontol 1999;34:797–808.
  128. Sung S, Yao Y, Uryu K, Yang H, Lee VM, Trojanowski JQ, et al: Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer’s disease. FASEB J 2004;18:323–325.
  129. Ancelin ML, Ritchie K: Lifelong endocrine fluctuations and related cognitive disorders. Curr Pharm Des 2005;11:4229–4252.
  130. Grundman M: Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr 2000;71:630S–636S.
  131. Saver JL, Kalafut M: Combination therapies and the theoretical limits of evidence-based medicine. Neuroepidemiology 2001;20:57–64.
  132. Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H: The GuidAge study: methodological issues – A 5-year double-blind randomized trial of the efficacy of EGb 761(R) for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 2006;67:S6–S11.

    External Resources

  133. Youdim KA, Joseph JA: A possible emerging role of phytochemicals in improving age-related neurological dysfunctions: a multiplicity of effects. Free Radic Biol Med 2001;30:583–594.
  134. Hollman PCH, Katan MB: Absorption, metabolism, and bioavailability of flavonoids; in Rice-Evans C, Packer L (eds): Flavonoids in Health and Disease. New York, Dekker, 1998, pp 483–522.
  135. Watanabe CM, Wolffram S, Ader P, Rimbach G, Packer L, Maguire JJ, et al: The in vivo neuromodulatory effects of the herbal medicine Ginkgo biloba. Proc Natl Acad Sci USA 2001;98:6577–6580.
  136. Longpré F, Garneau P, Christen Y, Ramassamy C: Protection by EGb 761 against the beta-amyloid-induced neurotoxicity: involvement of NF-kappaB, SIRT1, MAPKs pathways and inhibition of the amyloid fibrils formation. Free Radic Biol Med 2006;41:1781–1794.
  137. Rimbach G, Wolffram S, Watanabe C, Packer L, Gohil K: Effect of Ginkgo biloba (EGb 761) on differential gene expression. Pharmacopsychiatry 2003;36(suppl 1):S95–S99.
  138. DeFeudis FV: Effects of Ginkgo biloba extract (EGb 761) on gene expression: possible relevance to neurological disorders and age-associated cognitive impairment. Drug Dev Res 2002;57:214–235.
  139. Allain H, Raoul P, Lieury A, LeCoz F, Gandon JM, d’Arbigny P: Effect of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther 1993;15:549–558.
  140. Christen Y: Ginkgo biloba: from traditional medicine to molecular biology; in Packer L, Halliwell B, Ong CN (eds): Herbal and Traditional Medicine. Molecular Basis in Health and Disease Management. New York, Dekker, 2004, pp 154–164.
  141. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR: Altered plasma antioxidant status in subjects with Alzheimer’s disease and vascular dementia. Int J Geriatr Psychiatry 1998;13:840–845.
  142. Foy CJ, Passmore AP, Vahidassr MD, Young IS, Lawson JT: Plasma chain-breaking antioxidants in Alzheimer’s disease, vascular dementia and Parkinson’s disease. QJM 1999;92:39–45.
  143. Bourdel-Marchasson I, Delmas-Beauvieux MC, Peuchant E, Richard-Harston S, Decamps A, Reignier B, et al: Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 2001;30:235–241.
  144. Polidori MC, Mecocci P: Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J Alzheimers Dis 2002;4:517–522.
  145. Mecocci P, Polidori MC, Cherubini A, Ingegni T, Mattioli P, Catani M, et al: Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 2002;59:794–798.
  146. Helmer C, Peuchant E, Letenneur L, Bourdel-Marchasson I, Larrieu S, Dartigues JF, et al: Association between antioxidant nutritional indicators and the incidence of dementia: results from the PAQUID prospective cohort study. Eur J Clin Nutr 2003;57:1555–1561.
  147. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, et al: Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 2004;61:668–672.
  148. Cherubini A, Martin A, Andres-Lacueva C, Di Iorio A, Lamponi M, Mecocci P, et al: Vitamin E levels, cognitive impairment and dementia in older persons: the InCHIANTI study. Neurobiol Aging 2005;26:987–994.
  149. Riviere S, Birlouez-Aragon I, Vellas B: Plasma protein glycation in Alzheimer’s disease. Glycoconj J 1998;15:1039–1042.
  150. Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg HJ, Mann U, et al: Increased lipoprotein oxidation in Alzheimer’s disease. Free Radic Biol Med 2000;28:351–360.
  151. Ryglewicz D, Rodo M, Kunicki PK, Bednarska-Makaruk M, Graban A, Lojkowska W, et al: Plasma antioxidant activity and vascular dementia. J Neurol Sci 2002;203–204:195–197.
  152. Schmidt R, Hayn M, Reinhart B, Roob G, Schmidt H, Schumacher M, et al: Plasma antioxidants and cognitive performance in middle-aged and older adults: results of the Austrian Stroke Prevention Study. J Am Geriatr Soc 1998;46:1407–1410.
  153. Perkins AJ, Hendrie HC, Callahan CM, Gao S, Unverzagt FW, Xu Y, et al: Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am J Epidemiol 1999;150:37–44.
  154. Perrig WJ, Perrig P, Stahelin HB: The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc 1997;45:718–24.
  155. Lindeman RD, Romero LJ, Koehler KM, Liang HC, LaRue A, Baumgartner RN, et al: Serum vitamin B12, C and folate concentrations in the New Mexico elder health survey: correlations with cognitive and affective functions. J Am Coll Nutr 2000;19:68–76.
  156. Jimenez-Jimenez FJ, Molina JA, de Bustos F, Orti-Pareja M, Benito-Leon J, Tallon-Barranco A, et al: Serum levels of beta-carotene, alpha-carotene and vitamin A in patients with Alzheimer’s disease. Eur J Neurol 1999;6:495–497.
  157. Jimenez-Jimenez FJ, de Bustos F, Molina JA, Benito-Leon J, Tallon-Barranco A, Gasalla T, et al: Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer’s disease. J Neural Transm 1997;104:703–710.
  158. Ceballos-Picot I, Merad-Boudia M, Nicole A, Thevenin M, Hellier G, Legrain S, et al: Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer’s type – place of the extracellular glutathione peroxidase. Free Radic Biol Med 1996;20:579–587.
  159. Feillet-Coudray C, Tourtauchaux R, Niculescu M, Rock E, Tauveron I, Alexandre-Gouabau MC, et al: Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer’s disease. Free Radic Biol Med 1999;27:463–469.
  160. Kawamoto EM, Munhoz CD, Glezer I, Bahia VS, Caramelli P, Nitrini R, et al: Oxidative state in platelets and erythrocytes in aging and Alzheimer’s disease. Neurobiol Aging 2005;26:857–864.
  161. Migliore L, Fontana I, Trippi F, Colognato R, Coppede F, Tognoni G, et al: Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 2005;26:567–573.
  162. Snaedal J, Kristinsson J, Gunnarsdottir S, Olafsdottir A, Baldvinsson M, Johannesson T: Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer’s disease – a case-control study. Dement Geriatr Cogn Disord 1998;9:239–242.
  163. Roberts LJ 2nd, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, et al: Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998;273:13605–13612.
  164. Pratico D, MY Lee V, Trojanowski JQ, Rokach J, Fitzgerald GA: Increased F2-isoprostanes in Alzheimer’s disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 1998;12:1777–1783.
  165. Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ 2nd, Morrow JD: The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer’s disease patients. Am J Pathol 1999;155:863–868.
  166. Montine TJ, Beal MF, Cudkowicz ME, O’Donnell H, Margolin RA, McFarland L, et al: Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999;52:562–565.
  167. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR: Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer’s disease. Neurobiol Aging 1997;18:457–461.
  168. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, et al: Brain regional correspondence between Alzheimer’s disease histopathology and biomarkers of protein oxidation. J Neurochem 1995;65:2146–2156.
  169. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA: Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 1998;18:8126–8132.
  170. Lovell MA, Gabbita SP, Markesbery WR: Increased DNA oxidation and decreased levels of repair products in Alzheimer’s disease ventricular CSF. J Neurochem 1999;72:771–776.
  171. Lovell MA, Markesbery WR: Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch Neurol 2001;58:392–396.
  172. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Munch G: Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer’s disease and link to cognitive impairment. J Neurochem 2005;92:255–263.
  173. McIntosh LJ, Trush MA, Troncoso JC: Increased susceptibility of Alzheimer’s disease temporal cortex to oxygen free radical-mediated processes. Free Radic Biol Med 1997;23:183–190.
  174. Hayn M, Kremser K, Singewald N, Cairns N, Nemethova M, Lubec B, et al: Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down’s syndrome and Alzheimer’s disease. Life Sci 1996;59:537–544.
  175. Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B: An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer’s disease. J Neurochem 1997;68:2061–2069.
  176. Lovell MA, Ehmann WD, Butler SM, Markesbery WR: Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease. Neurology 1995;45:1594–1601.
  177. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, et al: Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer’s disease. Exp Neurol 1998;150:40–44.
  178. Nourooz-Zadeh J, Liu EH, Yhlen B, Anggard EE, Halliwell B: F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer’s disease. J Neurochem 1999;72:734–740.
  179. Reich EE, Markesbery WR, Roberts LJ 2nd, Swift LL, Morrow JD, Montine TJ: Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer’s disease. Am J Pathol 2001;158:293–297.
  180. Markesbery WR, Lovell MA: Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer’s disease. Neurobiol Aging 1998;19:33–36.
  181. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR: Regional membrane phospholipid alterations in Alzheimer’s disease. Neurochem Res 1998;23:81–88.
  182. Gabbita SP, Lovell MA, Markesbery WR: Increased nuclear DNA oxidation in the brain in Alzheimer’s disease. J Neurochem 1998;71:2034–2040.
  183. Gsell W, Conrad R, Hickethier M, Sofic E, Frolich L, Wichart I, et al: Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 1995;64:1216–1223.
  184. Mendelsohn AB, Belle SH, Stoehr GP, Ganguli M: Use of antioxidant supplements and its association with cognitive function in a rural elderly cohort: the MoVIES Project – Monongahela Valley Independent Elders Survey. Am J Epidemiol 1998;148:38–44.
  185. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D: Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 1997;145:33–41.
  186. Peacock JM, Folsom AR, Knopman DS, Mosley TH, Goff DC Jr, Szklo M; the Atherosclerosis Risk in Communities (ARIC) Study investigators: Dietary antioxidant intake and cognitive performance in middle-aged adults. Public Health Nutr 2000;3:337–343.
  187. Laurin D, Foley DJ, Masaki KH, White LR, Launer LJ: Vitamin E and C supplements and risk of dementia. JAMA 2002;288:2266–2268.
  188. Fillenbaum GG, Kuchibhatla MN, Hanlon JT, Artz MB, Pieper CF, Schmader KE, et al: Dementia and Alzheimer’s disease in community-dwelling elders taking vitamin C and/or vitamin E. Ann Pharmacother 2005;39:2009–2014.

  

Author Contacts

Dr. Yves Christen
24 rue Erlanger
FR–75016 Paris (France)
Tel. +33 144 96 1010, Fax +33 144 96 1199 E-Mail yves.christen@ipsen.com

  

Article Information

Y.C. is an employee of Ipsen.

Accepted: January 18, 2007
Published online: May 10, 2007
Number of Print Pages : 19
Number of Figures : 0, Number of Tables : 2, Number of References : 188

  

Publication Details

Dementia and Geriatric Cognitive Disorders

Vol. 24, No. 1, Year 2007 (Cover Date: June 2007)

Journal Editor: Chan-Palay, V. (New York, N.Y.)
ISSN: 1420–8008 (print), 1421–9824 (Online)

For additional information: http://www.karger.com/DEM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Abstract

Therapeutic interventions for the prodromal stages of dementia are currently being sought with a view to delaying if not preventing disease onset. Uncertainty as to whether cognitive disorder in a given individual will progress towards dementia and adverse drug side effects has led to hesitancy on the part of drug regulators to instigate preventive pharmacotherapies. In this context, antioxidant therapies may provide a low-risk alternative, targeting very early biological changes. While a growing body of knowledge demonstrates both the importance of oxidative stress in the aetiology of dementia and the efficacy of antioxidant treatment in animal and cellular models, studies in humans are presently inconclusive. While some antioxidants, notably flavonoid- or vitamin-rich diets, appear to lower the relative risk for Alzheimer’s disease in humans in observational studies, these results must be interpreted in the light of the biological complexity of the relationship between oxidative stress and neurodegeneration, and the methodological and theoretical shortcomings of studies conducted to date. A clearer understanding of these factors will assist in the interpretation of the results of the intervention studies which are now being undertaken; these studies being the only current means of establishing efficacy for preventive drug treatment of Alzheimer’s disease.

© 2007 S. Karger AG, Basel


  

Author Contacts

Dr. Yves Christen
24 rue Erlanger
FR–75016 Paris (France)
Tel. +33 144 96 1010, Fax +33 144 96 1199 E-Mail yves.christen@ipsen.com

  

Article Information

Y.C. is an employee of Ipsen.

Accepted: January 18, 2007
Published online: May 10, 2007
Number of Print Pages : 19
Number of Figures : 0, Number of Tables : 2, Number of References : 188

  

Publication Details

Dementia and Geriatric Cognitive Disorders

Vol. 24, No. 1, Year 2007 (Cover Date: June 2007)

Journal Editor: Chan-Palay, V. (New York, N.Y.)
ISSN: 1420–8008 (print), 1421–9824 (Online)

For additional information: http://www.karger.com/DEM


Article / Publication Details

First-Page Preview
Abstract of Review Article

Received: 9/25/2006
Accepted: 1/18/2007
Published online: 5/10/2007
Issue release date: June 2007

Number of Print Pages: 19
Number of Figures: 0
Number of Tables: 2

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: http://www.karger.com/DEM


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Katzman R, Fox PJ: The world-wide impact of dementia: projections of prevalence and costs; in Mayeux R, Christen Y (eds): Epidemiology of Alzheimer’s Disease. From Gene to Prevention. Berlin, Springer, 1999, pp 1–17.
  2. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.
  3. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37–46.
  4. Finkel T, Holbrook NJ: Oxidants, oxidative stress and the biology of ageing. Nature 2000;408:239–247.
  5. Christen Y: Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71:621S–629S.
  6. Arlt S, Beisiegel U, Kontush A: Lipid peroxidation in neurodegeneration: new insights into Alzheimer’s disease. Curr Opin Lipidol 2002;13:289–294.
  7. Butterfield DA, Castegna A, Lauderback CM, Drake J: Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death. Neurobiol Aging 2002;23:655–664.
  8. Abramov AY, Canevari L, Duchen MR: Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 2004;24:565–575.
  9. Berlin D, Chong G, Chertkow H, Bergman H, Phillips NA, Schipper HM: Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI. Neurobiol Aging 2004;25:465–474.
  10. Robson KJ, Lehmann DJ, Wimhurst VL, Livesey KJ, Combrinck M, Merryweather-Clarke AT, et al: Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer’s disease. J Med Genet 2004;41:261–265.
  11. Behl C, Moosmann B: Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic approach. Free Radic Biol Med 2002;33:182–191.
  12. Luchsinger JA, Tang MX, Shea S, Mayeux R: Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60:203–208.
  13. Floyd RA, Hensley K: Oxidative stress in brain aging: implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 2002;23:795–807.
  14. Engelhart MJ, Ruitenberg A, Meijer J, Kiliaan A, van Swieten JC, Hofman A, et al: Plasma levels of antioxidants are not associated with Alzheimer’s disease or cognitive decline. Dement Geriatr Cogn Disord 2005;19:134–139.
  15. Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, Lussier-Cacan S, et al: Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer’s disease is related to the apolipoprotein E genotype. Free Radic Biol Med 1999;27:544–553.
  16. Tamaoka A, Miyatake F, Matsuno S, Ishii K, Nagase S, Sahara N, et al: Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer’s disease. Neurology 2000;54:2319–2321.
  17. Delibas N, Ozcankaya R, Altuntas I: Clinical importance of erythrocyte malondialdehyde levels as a marker for cognitive deterioration in patients with dementia of Alzheimer type: a repeated study in 5-year interval. Clin Biochem 2002;35:137–141.
  18. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ: Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 2002;59:972–976.
  19. De Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al: Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006;27:394–401.
  20. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, et al: Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer’s disease. Neurobiol Aging 2003;24:915–919.
  21. Berr C, Richard MJ, Roussel AM, Bonithon-Kopp C: Systemic oxidative stress and cognitive performance in the population-based EVA study. Etude du Vieillissement Arteriel. Free Radic Biol Med 1998;24:1202–1208.
  22. Berr C, Balansard B, Arnaud J, Roussel AM, Alperovitch A: Cognitive decline is associated with systemic oxidative stress: the EVA study. Etude du Vieillissement Arteriel. J Am Geriatr Soc 2000;48:1285–1291.
  23. Berr C, Richard MJ, Gourlet V, Garrel C, Favier A: Enzymatic antioxidant balance and cognitive decline in aging – the EVA study. Eur J Epidemiol 2004;19:133–138.
  24. Polidori MC, Mattioli P, Aldred S, Cecchetti R, Stahl W, Griffiths H, et al: Plasma antioxidant status, immunoglobulin G oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord 2004;18:265–270.
  25. Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, et al: Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer’s disease. Ann Neurol 2002;52:175–179.
  26. Beckman KB, Ames BN: The free radical theory of aging matures. Physiol Rev 1998;78:547–581.
  27. Christen Y: Proteins and mutations: a new vision (molecular) of neurodegenerative diseases. J Soc Biol 2002;196:85–94.
  28. Yao Y, Zhukareva V, Sung S, Clark CM, Rokach J, Lee VM, et al: Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology 2003;61:475–478.
  29. Behl C, Davis J, Cole GM, Schubert D: Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun 1992;186:944–950.
  30. Harkany T, Hortobagyi T, Sasvari M, Konya C, Penke B, Luiten PG, et al: Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:963–1008.
  31. Christen Y, Droy-Lefaix M-T, Pasquier C, Packer L: Effects of Ginkgo biloba extract (EGb 761) on Alzheimer’s disease; in Poli G, Cadenas E, Packer L (eds): Free Radicals in Brain Pathophysiology. New York, Dekker, 2000, pp 411–423.
  32. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R: The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 2000;12:1882–1890.
  33. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, et al: Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 2002;99:12197–1202.
  34. Colciaghi F, Borroni B, Zimmermann M, Bellone C, Longhi A, Padovani A, et al: Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis 2004;16:454–460.
  35. Stackman RW, Eckenstein F, Frei B, Kulhanek D, Nowlin J, Quinn JF: Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer’s disease by chronic Ginkgo biloba treatment. Exp Neurol 2003;184:510–520.
  36. Joseph JA, Denisova NA, Arendash G, Gordon M, Diamond D, Shukitt-Hale B, et al: Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr Neurosci 2003;6:153–162.
  37. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, et al: Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001;22:993–1005.
  38. Joseph JA, Shukitt-Hale B, Denisova NA, Prior RL, Cao G, Martin A, et al: Long-term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits. J Neurosci 1998;18:8047–8055.
  39. Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G, Calabrese V: Nutritional approaches to combat oxidative stress in Alzheimer’s disease. J Nutr Biochem 2002;13:444.
  40. Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DL, Reiter RJ, et al: Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997;17:1683–1690.
  41. Xiao XQ, Zhang HY, Tang XC: Huperzine A attenuates amyloid beta-peptide fragment 25–35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res 2002;67:30–36.
  42. Medina S, Martinez M, Hernanz A: Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1–42. Free Radic Res 2002;36:1179–1184.
  43. Bruce AJ, Malfroy B, Baudry M: beta-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. Proc Natl Acad Sci USA 1996;93:2312–2316.
  44. Suuronen T, Kolehmainen P, Salminen A: Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. Biochem Pharmacol 2000;59:1589–1595.
  45. Hayako H, Hirai K, Kato K: Idebenone attenuates amyloid β-peptide-induced cell death rate hippocampal neuronal cell cultures (abstract). Jpn J Pharmacol 1997;73:245P.
  46. Galli RL, Shukitt-Hale B, Youdim KA, Joseph JA: Fruit polyphenolics and brain aging: nutritional interventions targeting age-related neuronal and behavioral deficits. Ann NY Acad Sci 2002;959:128–132.
  47. Fukui K, Omoi NO, Hayasaka T, Shinnkai T, Suzuki S, Abe K, et al: Cognitive impairment of rats caused by oxidative stress and aging, and its prevention by vitamin E. Ann NY Acad Sci 2002;959:275–284.
  48. Yamazaki N, Kiyota Y, Take Y, Miyamoto M, Nagawa Y, Nagaoka A: Effects of idebenone on memory impairment induced in ischemic and embolization models of cerebrovascular disturbance in rats. Arch Gerontol Geriatr 1989;8:213–224.
  49. Liu R, Liu IY, Bi X, Thompson RF, Doctrow SR, Malfroy B, et al: Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. Proc Natl Acad Sci USA 2003;100:8526–8531.
  50. Cohen-Salmon C, Venault P, Martin B, Raffalli-Sebille MJ, Barkats M, Clostre F, et al: Effects of Ginkgo biloba extract (EGb 761) on learning and possible actions on aging. J Physiol Paris 1997;91:291–300.
  51. Rogers EJ, Milhalik S, Orthiz D, Shea TB: Apple juice prevents oxidative stress and impaired cognitive performance caused by genetic and dietary deficiencies in mice. J Nutr Health Aging 2004;8:92–97.
  52. Milgram NW, Zicker SC, Head E, Muggenburg BA, Murphey H, Ikeda-Douglas CJ, et al: Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Neurobiol Aging 2002;23:737–745.
  53. Mattson MP, Duan W, Lee J, Guo Z: Suppression of brain aging and neurodegenerative disorders by dietary restriction and environmental enrichment: molecular mechanisms. Mech Ageing Dev 2001;122:757–778.
  54. Casadesus G, Shukitt-Hale B, Joseph JA: Qualitative versus quantitative caloric intake: are they equivalent paths to successful aging? Neurobiol Aging 2002;23:747–769.
  55. Grodstein F, Chen J, Willett WC: High-dose antioxidant supplements and cognitive function in community-dwelling elderly women. Am J Clin Nutr 2003;77:975–984.
  56. Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, et al: Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000;54:1265–1272.
  57. Maxwell CJ, Hicks MS, Hogan DB, Basran J, Ebly EM: Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. Dement Geriatr Cogn Disord 2005;20:45–51.
  58. Paleologos M, Cumming RG, Lazarus R: Cohort study of vitamin C intake and cognitive impairment. Am J Epidemiol 1998;148:45–50.
  59. Jama JW, Launer LJ, Witteman JC, den Breeijen JH, Breteler MM, Grobbee DE, et al: Dietary antioxidants and cognitive function in a population-based sample of older persons: the Rotterdam Study. Am J Epidemiol 1996;144:275–280.
  60. Gale CR, Martyn CN, Cooper C: Cognitive impairment and mortality in a cohort of elderly people. BMJ 1996;312:608–611.
  61. Ortega RM, Requejo AM, Andres P, Lopez-Sobaler AM, Quintas ME, Redondo MR, et al: Dietary intake and cognitive function in a group of elderly people. Am J Clin Nutr 1997;66:803–809.
  62. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS: Vitamin E and cognitive decline in older persons. Arch Neurol 2002;59:1125–1132.
  63. Ortega RM, Requejo AM, Lopez-Sobaler AM, Andres P, Navia B, Perea JM, et al: Cognitive function in elderly people is influenced by vitamin E status. J Nutr 2002;132:2065–2068.
  64. Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS, Aggarwal NT, et al: Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr 2005;81:508–514.
  65. La Rue A, Koehler KM, Wayne SJ, Chiulli SJ, Haaland KY, Garry PJ: Nutritional status and cognitive functioning in a normally aging sample: a 6-year assessment. Am J Clin Nutr 1997;65:20–29.
  66. Morris MC, Beckett LA, Scherr PA, Hebert LE, Bennett DA, Field TS, et al: Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:121–126.
  67. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, et al: Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004;61:82–88.
  68. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, et al: Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002;287:3223–3229.
  69. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, et al: Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002;287:3230–3237.
  70. Andrieu S, Gillette S, Amouyal K, Nourhashemi F, Reynish E, Ousset PJ, et al: Association of Alzheimer’s disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 2003;58:372–377.
  71. Dartigues JF, Carcaillon L, Helmer C, Lechevallier N, Lafuma A, Khoshnood B: Vasodilators and nootropics as predictors of dementia and mortality in the PAQUID cohort. J Am Geriatr Soc, in press.
  72. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, et al: Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 1997;153:185–192.
  73. Lemeshow S, Letenneur L, Dartigues JF, Lafont S, Orgogozo JM, Commenges D: Illustration of analysis taking into account complex survey considerations: the association between wine consumption and dementia in the PAQUID study – Personnes Ages Quid. Am J Epidemiol 1998;148:298–306.
  74. Commenges D, Scotet V, Renaud S, Jacqmin-Gadda H, Barberger-Gateau P, Dartigues JF: Intake of flavonoids and risk of dementia. Eur J Epidemiol 2000;16:357–363.
  75. Leibovici D, Ritchie K, Ledesert B, Touchon J: The effects of wine and tobacco consumption on cognitive performance in the elderly: a longitudinal study of relative risk. Int J Epidemiol 1999;28:77–81.
  76. Truelsen T, Thudium D, Gronbaek M: Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology 2002;59:1313–1319.
  77. Ruitenberg A, van Swieten JC, Witteman JC, Mehta KM, van Duijn CM, Hofman A, et al: Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 2002;359:281–286.
  78. Mukamal KJ, Kuller LH, Fitzpatrick AL, Longstreth WT Jr, Mittleman MA, Siscovick DS: Prospective study of alcohol consumption and risk of dementia in older adults. JAMA 2003;289:1405–1413.
  79. Luchsinger JA, Tang MX, Siddiqui M, Shea S, Mayeux R: Alcohol intake and risk of dementia. J Am Geriatr Soc 2004;52:540–546.
  80. Espeland MA, Coker LH, Wallace R, Rapp SR, Resnick SM, Limacher M, et al: Association between alcohol intake and domain-specific cognitive function in older women. Neuroepidemiology 2006;27:1–12.
  81. Youdim KA, Spencer JP, Schroeter H, Rice-Evans C: Dietary flavonoids as potential neuroprotectants. Biol Chem 2002;383:503–519.
  82. Dufouil C, Tzourio C, Brayne C, Berr C, Amouyel P, Alperovitch A: Influence of apolipoprotein E genotype on the risk of cognitive deterioration in moderate drinkers and smokers. Epidemiology 2000;11:280–284.
  83. Tanaka N, Asada T, Kinoshita T, Yamashita F, Uno M: Alcohol consumption and risk of dementia. Lancet 2002;360:491.
  84. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease: the Alzheimer’s Disease Cooperative Study. N Engl J Med 1997;336:1216–1222.
  85. Kilander L, Ohrvall M: Alpha-tocopherol and Alzheimer’s disease. N Engl J Med 1997;337:572–573.
  86. Pincus MM: Alpha-tocopherol and Alzheimer’s disease. N Engl J Med 1997;337:572; author reply 573.
  87. Tabet N, Birks J, Grimley Evans J: Vitamin E for Alzheimer’s disease. Cochrane Database Syst Rev 2000;CD002854.
  88. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–2388.
  89. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF; North American EGb Study Group: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327–1332.
  90. Kanowski S, Hoerr R: Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 2003;36:297–303.
  91. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M: A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr Alzheimer Res 2005;2:541–551.
  92. Van Dongen MC, van Rossum E, Kessels AG, Sielhorst HJ, Knipschild PG: The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 2000;48:1183–1194.
  93. Van Dongen M, van Rossum E, Kessels A, Sielhorst H, Knipschild P: Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol 2003;56:367–376.
  94. Birks J, Grimley EV, Van Dongen M: Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002;CD003120.
  95. Adair JC, Knoefel JE, Morgan N: Controlled trial of N-acetylcysteine for patients with probable Alzheimer’s disease. Neurology 2001;57:1515–1517.
  96. Hager K, Marahrens A, Kenklies M, Riederer P, Munch G: Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. Arch Gerontol Geriatr 2001;32:275–282.
  97. Gutzmann H, Hadler D: Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre study. J Neural Transm Suppl 1998;54:301–310.
  98. Gutzmann H, Kuhl KP, Hadler D, Rapp MA: Safety and efficacy of idebenone versus tacrine in patients with Alzheimer’s disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry 2002;35:12–18.
  99. Weyer G, Erzigkeit H, Hadler D, Kubicki S: Efficacy and safety of idebenone versus tacrine in patients with Alzheimer’s disease: a double-blind, placebo controlled multicentre study. Hum Psychopharmacol 1996;11:53–65.
  100. Weyer G, Babej-Dolle RM, Hadler D, Hofmann S, Herrmann WM: A controlled study of 2 doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology 1997;36:73–82.
  101. Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, et al: Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease. Neurology 2003;61:1498–1502.
  102. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, et al: Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet 1991;337:1304–1308.
  103. Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, et al: Treatment of Alzheimer’s disease with clioquinol. Dement Geriatr Cogn Disord 2001;12:408–414.
  104. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, et al: Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60:1685–1691.
  105. Wolters M, Hickstein M, Flintermann A, Tewes U, Hahn A: Cognitive performance in relation to vitamin status in healthy elderly German women – the effect of 6-month multivitamin supplementation. Prev Med 2005;41:253–259.
  106. Mix JA, Crews WD Jr: A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol 2002;17:267–277.
  107. Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R: Ginkgo for memory enhancement: a randomized controlled trial. JAMA 2002;288:835–840.
  108. Martin A, Cherubini A, Andres-Lacueva C, Paniagua M, Joseph J: Effects of fruits and vegetables on levels of vitamins E and C in the brain and their association with cognitive performance. J Nutr Health Aging 2002;6:392–404.
  109. Dai Q, Borenstein AR, Wu Y, Jackson JC, Larson EB: Fruit and vegetable juices and Alzheimer’s disease: the Kame Project. Am J Med 2006;119:751–759.
  110. Yaffe K, Clemons TE, McBee WL, Lindblad AS: Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology 2004;63:1705–1707.
  111. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC: Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450–1456.
  112. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC: Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444–1449.
  113. Bowry VW, Ingold KU, Stocker R: Vitamin E in human low-density lipoprotein: when and how this antioxidant becomes a pro-oxidant. Biochem J 1992;288:341–344.
  114. Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P, Lunec J: Vitamin C exhibits pro-oxidant properties. Nature 1998;392:559.
  115. Halliwell B: The antioxidant paradox. Lancet 2000;355:1179–1180.
  116. Christen S, Woodall AA, Shigenaga MK, Southwell-Keely PT, Duncan MW, Ames BN: gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: physiological implications. Proc Natl Acad Sci USA 1997;94:3217–3222.
  117. Tangney CC, Bienias JL, Evans DA, Morris MC: Reasonable estimates of serum vitamin E, vitamin C, and beta-cryptoxanthin are obtained with a food frequency questionnaire in older black and white adults. J Nutr 2004;134:927–934.
  118. Riviere S, Lauque S, Vellas B: Health promotion programme: nutrition and Alzheimer’s disease. J Nutr Health Aging 1998;2:101–106.
  119. Meydani M: Antioxidants in the prevention of chronic diseases. Nutr Clin Care 2002;5:47–49.
  120. Shea TB, Rogers E, Ashline D, Ortiz D, Sheu MS: Apolipoprotein E deficiency promotes increased oxidative stress and compensatory increases in antioxidants in brain tissue. Free Radic Biol Med 2002;33:1115–1120.
  121. McCaddon A, Hudson P, Hill D, Barber J, Lloyd A, Davies G, et al: Alzheimer’s disease and total plasma aminothiols. Biol Psychiatry 2003;53:254–260.
  122. Miyata M, Smith JD: Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14:55–61.
  123. Willett WC, Stampfer MJ: Clinical practice: What vitamins should I be taking, doctor? N Engl J Med 2001;345:1819–1824.
  124. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, et al: Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005;293:1338–1347.
  125. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al: Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA 2005;294:56–65.
  126. Laurin D, Masaki KH, Foley DJ, White LR, Launer LJ: Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study. Am J Epidemiol 2004;159:959–967.
  127. Shukitt-Hale B, Smith DE, Meydani M, Joseph JA: The effects of dietary antioxidants on psychomotor performance in aged mice. Exp Gerontol 1999;34:797–808.
  128. Sung S, Yao Y, Uryu K, Yang H, Lee VM, Trojanowski JQ, et al: Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer’s disease. FASEB J 2004;18:323–325.
  129. Ancelin ML, Ritchie K: Lifelong endocrine fluctuations and related cognitive disorders. Curr Pharm Des 2005;11:4229–4252.
  130. Grundman M: Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr 2000;71:630S–636S.
  131. Saver JL, Kalafut M: Combination therapies and the theoretical limits of evidence-based medicine. Neuroepidemiology 2001;20:57–64.
  132. Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H: The GuidAge study: methodological issues – A 5-year double-blind randomized trial of the efficacy of EGb 761(R) for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 2006;67:S6–S11.

    External Resources

  133. Youdim KA, Joseph JA: A possible emerging role of phytochemicals in improving age-related neurological dysfunctions: a multiplicity of effects. Free Radic Biol Med 2001;30:583–594.
  134. Hollman PCH, Katan MB: Absorption, metabolism, and bioavailability of flavonoids; in Rice-Evans C, Packer L (eds): Flavonoids in Health and Disease. New York, Dekker, 1998, pp 483–522.
  135. Watanabe CM, Wolffram S, Ader P, Rimbach G, Packer L, Maguire JJ, et al: The in vivo neuromodulatory effects of the herbal medicine Ginkgo biloba. Proc Natl Acad Sci USA 2001;98:6577–6580.
  136. Longpré F, Garneau P, Christen Y, Ramassamy C: Protection by EGb 761 against the beta-amyloid-induced neurotoxicity: involvement of NF-kappaB, SIRT1, MAPKs pathways and inhibition of the amyloid fibrils formation. Free Radic Biol Med 2006;41:1781–1794.
  137. Rimbach G, Wolffram S, Watanabe C, Packer L, Gohil K: Effect of Ginkgo biloba (EGb 761) on differential gene expression. Pharmacopsychiatry 2003;36(suppl 1):S95–S99.
  138. DeFeudis FV: Effects of Ginkgo biloba extract (EGb 761) on gene expression: possible relevance to neurological disorders and age-associated cognitive impairment. Drug Dev Res 2002;57:214–235.
  139. Allain H, Raoul P, Lieury A, LeCoz F, Gandon JM, d’Arbigny P: Effect of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther 1993;15:549–558.
  140. Christen Y: Ginkgo biloba: from traditional medicine to molecular biology; in Packer L, Halliwell B, Ong CN (eds): Herbal and Traditional Medicine. Molecular Basis in Health and Disease Management. New York, Dekker, 2004, pp 154–164.
  141. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR: Altered plasma antioxidant status in subjects with Alzheimer’s disease and vascular dementia. Int J Geriatr Psychiatry 1998;13:840–845.
  142. Foy CJ, Passmore AP, Vahidassr MD, Young IS, Lawson JT: Plasma chain-breaking antioxidants in Alzheimer’s disease, vascular dementia and Parkinson’s disease. QJM 1999;92:39–45.
  143. Bourdel-Marchasson I, Delmas-Beauvieux MC, Peuchant E, Richard-Harston S, Decamps A, Reignier B, et al: Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 2001;30:235–241.
  144. Polidori MC, Mecocci P: Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J Alzheimers Dis 2002;4:517–522.
  145. Mecocci P, Polidori MC, Cherubini A, Ingegni T, Mattioli P, Catani M, et al: Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 2002;59:794–798.
  146. Helmer C, Peuchant E, Letenneur L, Bourdel-Marchasson I, Larrieu S, Dartigues JF, et al: Association between antioxidant nutritional indicators and the incidence of dementia: results from the PAQUID prospective cohort study. Eur J Clin Nutr 2003;57:1555–1561.
  147. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, et al: Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 2004;61:668–672.
  148. Cherubini A, Martin A, Andres-Lacueva C, Di Iorio A, Lamponi M, Mecocci P, et al: Vitamin E levels, cognitive impairment and dementia in older persons: the InCHIANTI study. Neurobiol Aging 2005;26:987–994.
  149. Riviere S, Birlouez-Aragon I, Vellas B: Plasma protein glycation in Alzheimer’s disease. Glycoconj J 1998;15:1039–1042.
  150. Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg HJ, Mann U, et al: Increased lipoprotein oxidation in Alzheimer’s disease. Free Radic Biol Med 2000;28:351–360.
  151. Ryglewicz D, Rodo M, Kunicki PK, Bednarska-Makaruk M, Graban A, Lojkowska W, et al: Plasma antioxidant activity and vascular dementia. J Neurol Sci 2002;203–204:195–197.
  152. Schmidt R, Hayn M, Reinhart B, Roob G, Schmidt H, Schumacher M, et al: Plasma antioxidants and cognitive performance in middle-aged and older adults: results of the Austrian Stroke Prevention Study. J Am Geriatr Soc 1998;46:1407–1410.
  153. Perkins AJ, Hendrie HC, Callahan CM, Gao S, Unverzagt FW, Xu Y, et al: Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am J Epidemiol 1999;150:37–44.
  154. Perrig WJ, Perrig P, Stahelin HB: The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc 1997;45:718–24.
  155. Lindeman RD, Romero LJ, Koehler KM, Liang HC, LaRue A, Baumgartner RN, et al: Serum vitamin B12, C and folate concentrations in the New Mexico elder health survey: correlations with cognitive and affective functions. J Am Coll Nutr 2000;19:68–76.
  156. Jimenez-Jimenez FJ, Molina JA, de Bustos F, Orti-Pareja M, Benito-Leon J, Tallon-Barranco A, et al: Serum levels of beta-carotene, alpha-carotene and vitamin A in patients with Alzheimer’s disease. Eur J Neurol 1999;6:495–497.
  157. Jimenez-Jimenez FJ, de Bustos F, Molina JA, Benito-Leon J, Tallon-Barranco A, Gasalla T, et al: Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer’s disease. J Neural Transm 1997;104:703–710.
  158. Ceballos-Picot I, Merad-Boudia M, Nicole A, Thevenin M, Hellier G, Legrain S, et al: Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer’s type – place of the extracellular glutathione peroxidase. Free Radic Biol Med 1996;20:579–587.
  159. Feillet-Coudray C, Tourtauchaux R, Niculescu M, Rock E, Tauveron I, Alexandre-Gouabau MC, et al: Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer’s disease. Free Radic Biol Med 1999;27:463–469.
  160. Kawamoto EM, Munhoz CD, Glezer I, Bahia VS, Caramelli P, Nitrini R, et al: Oxidative state in platelets and erythrocytes in aging and Alzheimer’s disease. Neurobiol Aging 2005;26:857–864.
  161. Migliore L, Fontana I, Trippi F, Colognato R, Coppede F, Tognoni G, et al: Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 2005;26:567–573.
  162. Snaedal J, Kristinsson J, Gunnarsdottir S, Olafsdottir A, Baldvinsson M, Johannesson T: Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer’s disease – a case-control study. Dement Geriatr Cogn Disord 1998;9:239–242.
  163. Roberts LJ 2nd, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, et al: Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998;273:13605–13612.
  164. Pratico D, MY Lee V, Trojanowski JQ, Rokach J, Fitzgerald GA: Increased F2-isoprostanes in Alzheimer’s disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 1998;12:1777–1783.
  165. Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ 2nd, Morrow JD: The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer’s disease patients. Am J Pathol 1999;155:863–868.
  166. Montine TJ, Beal MF, Cudkowicz ME, O’Donnell H, Margolin RA, McFarland L, et al: Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999;52:562–565.
  167. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR: Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer’s disease. Neurobiol Aging 1997;18:457–461.
  168. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, et al: Brain regional correspondence between Alzheimer’s disease histopathology and biomarkers of protein oxidation. J Neurochem 1995;65:2146–2156.
  169. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA: Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 1998;18:8126–8132.
  170. Lovell MA, Gabbita SP, Markesbery WR: Increased DNA oxidation and decreased levels of repair products in Alzheimer’s disease ventricular CSF. J Neurochem 1999;72:771–776.
  171. Lovell MA, Markesbery WR: Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch Neurol 2001;58:392–396.
  172. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Munch G: Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer’s disease and link to cognitive impairment. J Neurochem 2005;92:255–263.
  173. McIntosh LJ, Trush MA, Troncoso JC: Increased susceptibility of Alzheimer’s disease temporal cortex to oxygen free radical-mediated processes. Free Radic Biol Med 1997;23:183–190.
  174. Hayn M, Kremser K, Singewald N, Cairns N, Nemethova M, Lubec B, et al: Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down’s syndrome and Alzheimer’s disease. Life Sci 1996;59:537–544.
  175. Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B: An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer’s disease. J Neurochem 1997;68:2061–2069.
  176. Lovell MA, Ehmann WD, Butler SM, Markesbery WR: Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease. Neurology 1995;45:1594–1601.
  177. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, et al: Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer’s disease. Exp Neurol 1998;150:40–44.
  178. Nourooz-Zadeh J, Liu EH, Yhlen B, Anggard EE, Halliwell B: F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer’s disease. J Neurochem 1999;72:734–740.
  179. Reich EE, Markesbery WR, Roberts LJ 2nd, Swift LL, Morrow JD, Montine TJ: Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer’s disease. Am J Pathol 2001;158:293–297.
  180. Markesbery WR, Lovell MA: Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer’s disease. Neurobiol Aging 1998;19:33–36.
  181. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR: Regional membrane phospholipid alterations in Alzheimer’s disease. Neurochem Res 1998;23:81–88.
  182. Gabbita SP, Lovell MA, Markesbery WR: Increased nuclear DNA oxidation in the brain in Alzheimer’s disease. J Neurochem 1998;71:2034–2040.
  183. Gsell W, Conrad R, Hickethier M, Sofic E, Frolich L, Wichart I, et al: Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 1995;64:1216–1223.
  184. Mendelsohn AB, Belle SH, Stoehr GP, Ganguli M: Use of antioxidant supplements and its association with cognitive function in a rural elderly cohort: the MoVIES Project – Monongahela Valley Independent Elders Survey. Am J Epidemiol 1998;148:38–44.
  185. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D: Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 1997;145:33–41.
  186. Peacock JM, Folsom AR, Knopman DS, Mosley TH, Goff DC Jr, Szklo M; the Atherosclerosis Risk in Communities (ARIC) Study investigators: Dietary antioxidant intake and cognitive performance in middle-aged adults. Public Health Nutr 2000;3:337–343.
  187. Laurin D, Foley DJ, Masaki KH, White LR, Launer LJ: Vitamin E and C supplements and risk of dementia. JAMA 2002;288:2266–2268.
  188. Fillenbaum GG, Kuchibhatla MN, Hanlon JT, Artz MB, Pieper CF, Schmader KE, et al: Dementia and Alzheimer’s disease in community-dwelling elders taking vitamin C and/or vitamin E. Ann Pharmacother 2005;39:2009–2014.